Literature DB >> 12044244

Chemoprevention of lung cancer.

Edward S Kim1, Fadlo R Khuri.   

Abstract

Lung cancer is the leading cause of death worldwide. Its overall survival rate has improved only slightly, and surgery, radiotherapy, and chemotherapy remain the mainstays of current treatment. Therapies with novel targeted agents are currently under active investigation in all settings of treatment including chemoprevention, defined as the use of natural or synthetic agents to interrupt the process of carcinogenesis and to prevent or delay tumor occurrence. Thus, chemoprevention describes the collaborative efforts of researchers in basic science and clinical settings who study the biology of lung cancer with the hope of uncovering new mechanisms of treatment. Because lung cancer has become an increasingly difficult problem to treat with standard therapies, chemopreventive strategies have been developed. Small molecule compounds that target specific receptors or mutations will play an increasingly significant role in treatment of lung cancer because the side effect profiles of such agents are tolerable and they may be more effective than other treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044244     DOI: 10.1007/s11912-002-0010-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  39 in total

1.  Randomized trial of supplemental beta-carotene to prevent second head and neck cancer.

Authors:  S T Mayne; B Cartmel; M Baum; G Shor-Posner; B G Fallon; K Briskin; J Bean; T Zheng; D Cooper; C Friedman; W J Goodwin
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

2.  Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.

Authors:  D M Shin; F R Khuri; B Murphy; A S Garden; G Clayman; M Francisco; D Liu; B S Glisson; L Ginsberg; V Papadimitrakopoulou; J Myers; W Morrison; A Gillenwater; K K Ang; S M Lippman; H Goepfert; W K Hong
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

3.  Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer.

Authors:  S E Benner; T F Pajak; J Stetz; S M Lippman; W K Hong; S P Schantz; M J Gallagher; G Shenouda
Journal:  J Natl Cancer Inst       Date:  1994-12-07       Impact factor: 13.506

4.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

5.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

6.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.

Authors:  N van Zandwijk; O Dalesio; U Pastorino; N de Vries; H van Tinteren
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

7.  Second respiratory and upper digestive tract cancers after oral cancer.

Authors:  B S Tepperman; P J Fitzpatrick
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

8.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

9.  Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.

Authors:  S M Lippman; J G Batsakis; B B Toth; R S Weber; J J Lee; J W Martin; G L Hays; H Goepfert; W K Hong
Journal:  N Engl J Med       Date:  1993-01-07       Impact factor: 91.245

10.  The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial.

Authors:  A M Arnold; G P Browman; M N Levine; T D'Souza; B Johnstone; P Skingley; L Turner-Smith; R Cayco; L Booker; M Newhouse
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.